Femasys Inc. (FEMY) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 5, 2026, details a material definitive agreement entered into by Femasys Inc. (the "Company") on August 7, 2026. The Company, a Delaware corporation trading on NASDAQ, executed a private placement of equity securities with certain accredited investors. The transaction closed on August 10, 2026.
Key Financial Metrics and Transaction Details
The filing does not provide historical revenue, profit, cash flow, or margin data. The primary financial metric disclosed relates to the capital raise:
- Gross Proceeds: Approximately $30.0 million (before offering expenses).
- Securities Issued:
- 5,013,559 shares of Common Stock at $3.20 per share.
- 4,361,440 Pre-Funded Warrants at $3.1999 per share.
- 18,749,998 accompanying Warrants (9,374,999 Common Warrants and 9,374,999 Milestone Warrants).
- Warrant Exercise Price: $2.95 per share for both Common and Milestone Warrants.
- Insider Participation: Five Company executives (CEO, CFO, COO, CTO, and Chief Clinical and Medical Affairs Officer) purchased securities for an aggregate of approximately $134,000.
Material Changes and Governance
The filing reports significant changes to the Company's capital structure and board governance:
- Board Representation: Under a Side Letter with Lead Investor Nantahala Capital Management, LLC, the Company agreed to appoint up to two individuals designated by the Lead Investor to the Board of Directors, subject to minimum ownership thresholds. The Lead Investor also retains the right to designate a non-voting Board observer.
- Termination of Prior Rights: On August 5 and 6, 2026, the Lead Lender from a prior Convertible Note Purchase Agreement (dated November 3, 2025) terminated its rights to nominate a Board member and designate a non-voting observer.
- Registration Rights: The Company agreed to file a resale registration statement covering 100% of the shares issuable upon exercise of the new warrants within 30 days of the Closing Date.
Outlook, Risks, and Milestones
The transaction includes specific performance milestones tied to the exercisability of the Milestone Warrants:
- Revenue Milestone: The Company must achieve U.S. revenue of at least $1,500,000 in any fiscal quarter.
- Stock Price Milestone: The volume-weighted average price of the Common Stock must equal or exceed 130% of the exercise price ($2.95) for at least 20 of 30 consecutive trading days.
- Ownership Limitations: Warrants cannot be exercised if the holder would beneficially own more than 4.99% (or up to 9.99% with notice) of outstanding Common Stock.
- Risk Factors: The filing notes there is no established public trading market for the Warrants, and the Company does not intend to list them on a national securities exchange.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting offering expenses.
- Confirm the filing and effectiveness date of the resale Registration Statement required within 30 days of August 10, 2026.
- Monitor the Company's quarterly U.S. revenue reports to determine if the $1.5 million threshold for Milestone Warrants is met.
- Review the Company's stock price performance to assess the likelihood of the 130% price threshold being achieved.
- Check subsequent filings for the appointment of the two Designees to the Board of Directors by Nantahala Capital Management.